Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Phase I Trial
Targeted Tolerance Induction in Pemphigus Vulgaris: A Synthesis of Phase I Clinical and Preclinical Evidence for TPM203 Nanoparticles
Posted inClinical Updates news

Targeted Tolerance Induction in Pemphigus Vulgaris: A Synthesis of Phase I Clinical and Preclinical Evidence for TPM203 Nanoparticles

Posted by MedXY By MedXY 03/06/2026
This review evaluates TPM203, a novel nanoparticle-based therapy for Pemphigus Vulgaris, detailing its safety profile, rapid pharmacokinetics, and ability to modulate regulatory T-cell and memory B-cell populations to induce immune tolerance.
Read More
  • Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial
  • Cellular Therapy for In-Utero Myelomeningocele Repair: Results from the CuRe Phase 1 Trial
  • Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia
  • Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia
  • Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in